TMO.US Weekly Report · 2026-W32
Thermo Fisher Scientific continues its uptrend this week with a 3.43% weekly gain, breaking out of a prior consolidation zone. The stock reached a new weekly high of $594.26 on Friday, closing strong. Simultaneously, company executives engaged in some insider trading while institutional sentiment remains constructive, with target prices offering 6% upside from current levels.
Price Action
Weekly close at $594.00, up 3.43% from the prior week’s close of $574.30 (July 31). The weekly range spans from a high of $594.26 to a low of $562.50 (August 4), representing a 5.6% intra-week swing.
Daily progression shows consolidation on August 3–4, followed by consecutive gains through August 5–7, with Friday closing as a strong bullish bar. Weekly trading volume totaled 8.99 million shares, averaging 1.798 million per day—notably below the 60-day average of approximately 2.5 million, indicating the rally was driven by existing capital repositioning rather than fresh inflows into the stock.
Valuation
Current P/E of 30.78x places the stock in the 18.8th percentile over the past three years, representing an undervalued position. P/B stands at 4.17x. Institutional target price of $631.42 implies 6% upside, though this appears conservative relative to the recent strong momentum.
Earnings & Consensus
Latest Q2 2026 results show EPS of $4.6792, up 9.38% year-over-year and 5.6% sequentially versus Q1’s $4.43. Revenue reached $11.994 billion (+10.49% YoY), with net profit at $1.736 billion (+7.36% YoY).
Earnings growth exhibits a revenue-centric pattern (revenue > profit > EPS), reflecting scale expansion amid margin pressure. At the latest consensus snapshot, full-year 2026 EPS estimate is $26.256. With YTD Q2 cumulative EPS at $4.6792, the company must deliver approximately $21.6 in H2 earnings to meet annual expectations—a meaningful bar.
Capital Flow & Institutions
Capital: Net inflows dominated, with retail (small orders) contributing $1,610.07 in net buy pressure, mid-tier at $473.99, and large orders at $565.14. Retail participation peaked, signaling warmer sentiment in the retail segment.
Institutions: Of 30 analysts, 19 rate “strong buy”, 3 “buy”, 6 “hold”, and 0 “sell”—overwhelmingly bullish. Ratings were last updated August 4, providing timely context. Ranked #1 among 54 peers in its sector (Life Sciences Tools & Services).
Weekly Developments
Executive insiders dominated headlines. CEO Marc Casper sold $8.01 million in common stock on August 6; the Senior VP and Chief HR Officer disposed of over $3.3 million. Insider selling, while notable, should not be reflexively interpreted as bearish given the constructive institutional backdrop.
The stock outperformed the broader market on Friday, providing momentum into the week’s close.
Key News (by relevance):
- CEO Marc Casper Sells $8.01 Million in Common Stock
- SVP and Chief HR Officer Sells Over $3.3 Million in Stock
- Thermo Fisher Stock Rises Friday, Outperforms Market
- 2026 Q2 Summary: Revenue $11.9B, EPS $4.68
- Thermo Fisher Rated Buy on Recovery Breadth, Conservative Guidance, Attractive Valuation
Takeaway
This week’s steady advance reflects convergence across three dimensions: valuation at historical lows, institutional enthusiasm, and net capital inflows. However, volume contraction, insider selling, and conservative target pricing warrant caution on near-term follow-through. The critical watch ahead is H2 earnings delivery and any potential adjustments to full-year EPS guidance. Investor focus should remain on whether the company can sustain margin recovery amid the scale growth narrative.